Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
2. Dexilant
3. Dexlansoprazole Sesquihydrate
4. Lansoprazole, R Isomer
5. Lansoprazole, R-isomer
6. R Lansoprazole
7. R-isomer Lansoprazole
8. R-lansoprazole
9. T 168390
10. T-168390
11. T168390
12. Tak 390
13. Tak 390mr
14. Tak-390
15. Tak-390mr
16. Tak390
17. Tak390mr
1. (r)-lansoprazole
2. 138530-94-6
3. Kapidex
4. R-(+)-lansoprazole
5. Dexilant
6. Dexilant Solutab
7. Tak 390
8. Tak-390
9. Lansoprazole R-form
10. Lansoprazole, (r)-
11. T 168390
12. (r)-(+)-lansoprazole
13. T-168390
14. Uye4t5i70x
15. (r)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole
16. Nsc-758710
17. 2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
18. Tak-390mr
19. 1h-benzimidazole, 2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-
20. Dexlansoprazole [usan]
21. Unii-uye4t5i70x
22. Dexlansoprazole (inn/usan)
23. Dexlansoprazole [usan:inn]
24. (+)-lansoprazol
25. 2-[(r)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
26. Dexilant (tn)
27. (+)-2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1h-benzimidazole
28. (+)-2-((r)-{(3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl}sulfinyl)-1h-benzimidazole
29. 1h-benzimidazole, 2-[(r)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-
30. Schembl44975
31. Dexlansoprazole [inn]
32. Dexlansoprazole [vandf]
33. Gtpl5487
34. Dexlansoprazole [mart.]
35. Chembl1201863
36. Dexlansoprazole [who-dd]
37. Lansoprazole R-form [mi]
38. 2-[(r)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole
39. Chebi:135931
40. Hms3652c14
41. Zinc599734
42. Amy25226
43. Bdbm50247930
44. Dexlansoprazole [orange Book]
45. Hy-13662b
46. Mfcd13196699
47. S4099
48. Akos025290765
49. Ccg-213301
50. Db05351
51. Nsc 758710
52. Pb33188
53. 2-[(r)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1h-benzimidazole
54. Ncgc00386267-03
55. Ac-26449
56. As-18086
57. Sw219466-1
58. D08903
59. Ab01563023_01
60. Ab01563023_02
61. Q5268339
62. (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
63. (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole
64. (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1h-benzimidazole
65. (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
66. (r)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1h-benzimidazole
67. 2-[(r)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl]-1h-1,3-benzodiazole
| Molecular Weight | 369.4 g/mol |
|---|---|
| Molecular Formula | C16H14F3N3O2S |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 369.07588236 g/mol |
| Monoisotopic Mass | 369.07588236 g/mol |
| Topological Polar Surface Area | 87.1 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 480 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Dexilant |
| PubMed Health | Dexlansoprazole (By mouth) |
| Drug Classes | Gastric Acid Secretion Inhibitor |
| Drug Label | The active ingredient in DEXILANT (dexlansoprazole) delayed-release capsules, a proton pump inhibitor, is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion... |
| Active Ingredient | Dexlansoprazole |
| Dosage Form | Capsule, delayed release |
| Route | Oral |
| Strength | 60mg; 30mg |
| Market Status | Prescription |
| Company | Takeda Pharms Usa |
| 2 of 4 | |
|---|---|
| Drug Name | Dexlansoprazole |
| PubMed Health | Dexlansoprazole (By mouth) |
| Drug Classes | Gastric Acid Secretion Inhibitor |
| Drug Label | The active ingredient in DEXILANT (dexlansoprazole) delayed-release capsules, a proton pump inhibitor, is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion... |
| Active Ingredient | Dexlansoprazole |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 60mg |
| Market Status | Tentative Approval |
| Company | Par Pharm |
| 3 of 4 | |
|---|---|
| Drug Name | Dexilant |
| PubMed Health | Dexlansoprazole (By mouth) |
| Drug Classes | Gastric Acid Secretion Inhibitor |
| Drug Label | The active ingredient in DEXILANT (dexlansoprazole) delayed-release capsules, a proton pump inhibitor, is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion... |
| Active Ingredient | Dexlansoprazole |
| Dosage Form | Capsule, delayed release |
| Route | Oral |
| Strength | 60mg; 30mg |
| Market Status | Prescription |
| Company | Takeda Pharms Usa |
| 4 of 4 | |
|---|---|
| Drug Name | Dexlansoprazole |
| PubMed Health | Dexlansoprazole (By mouth) |
| Drug Classes | Gastric Acid Secretion Inhibitor |
| Drug Label | The active ingredient in DEXILANT (dexlansoprazole) delayed-release capsules, a proton pump inhibitor, is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion... |
| Active Ingredient | Dexlansoprazole |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 60mg |
| Market Status | Tentative Approval |
| Company | Par Pharm |
Dexlansoprazole is indicated for healing all grades of erosive esophagitis (EE), maintaining and healing of EE and relief of heartburn, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).
FDA Label
Dexlansoprazole is a proton pump inhibitor (PPI) and is included in the drug class of antisecretory compounds. It blocks the final step of gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the parietal cells on gastric mucosa.
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
A - Alimentary tract and metabolism
A02 - Drugs for acid related disorders
A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BC - Proton pump inhibitors
A02BC06 - Dexlansoprazole
Absorption
After oral administration, the peak plasma concentration increases approximately dose proportionally. The dual delayed release formulation achieves two plasma concentration peaks, where the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. The delivery technology of dexlansoprazole MR is designed to release the drug in two separate pH-dependent phases, the first in the proximal duodenum (25% of total drug dose) and the second (75% of total drug dose) in the more distal small intestine. The median time (Tmax) to peak plasma concentrations (Cmax) of 30 mg dexlansoprazole was 4 hours and ranged from 1 to 6 hours with the Cmax value of 688 ng/mL. AUC was found to be 3275 (ngh/mL).
Route of Elimination
Dexlansoprazole is cleared from the body by either fecal excretion (50.7%) or renal excretion (47.6%) following oral ingestion, with no unchanged drug detected in the urine.
Volume of Distribution
The apparent volume of distribution after multiple doses in symptomatic GERD patients was 40.3 L.
Clearance
Apparent clearance (CL/F) in healthy subjects was 11.4 to 11.6 L/hour, respectively, after five days of 30 or 60 mg once daily administration.
Dexlansoprazole is extensively metabolized in the liver by oxidation, reduction, and subsequent formation of sulfate, glucuronide and glutathione conjugates to inactive metabolites. Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system including hydroxylation mainly by CYP2C19, and oxidation to the sulfone by CYP3A4. Dexlansoprazole is the major circulating component in plasma regardless of CYP2C19 metabolizer status. In CYP2C19 intermediate and extensive metabolizers, the major plasma metabolites are 5-hydroxy dexlansoprazole and its glucuronide conjugate, while in CYP2C19 poor metabolizers dexlansoprazole sulfone is the major plasma metabolite.
Lansoprazole has known human metabolites that include 5-Hydroxylansoprazole and Lansoprazole Sulfone.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Dexlansoprazole is eliminated with a half-life of approximately one to two hours in healthy subjects and in patients with symptomatic GERD.
Dexlansoprazole inhibits the H/K ATPase enzyme, which is involved in the secretion of hydrochloric acid, hydrolyzing ATP and exchanging H+ ions from the cytoplasm for K+ ions in the secretory canaliculus, which results in HCl secretion into the gastric lumen. Dexlansoprazole inhibits this effect of H/K ATPase by demonstrating a high degree of activation in the acidic environment. After passing through the liver and reaching the gastric parietal cells activated by a meal, PPIs undergo protonation in the acidic pH environment, followed by conversion to sulphenamide which represents the active form of the drug. Sulphenamide inhibits the activity of the proton pump and hence the transport of hydrogen ions into the gastric lumen via covalent binding to the SH groups of the cysteine residues of H/K ATPase. The delivery technology of dexlansoprazole MR is designed to release the drug in two separate pH-dependent phases, the first in the proximal duodenum (25% of total drug dose) and the second (75% of total drug dose) in the more distal small intestine. Dexlansoprazole reduces both basal and stimulated gastric acid secretion.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38997
Submission : 2023-12-04
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34971
Submission : 2020-09-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27834
Submission : 2014-02-06
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-09-20
Pay. Date : 2016-07-01
DMF Number : 24815
Submission : 2011-04-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23722
Submission : 2010-04-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25235
Submission : 2011-08-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26087
Submission : 2012-05-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25111
Submission : 2011-06-30
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-03-22
Pay. Date : 2012-11-23
DMF Number : 24503
Submission : 2010-12-21
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm : Unit-IV, Plot No. 34B, 40B & 60B, J.N Pharma City, Thanam (V), Parawada (M), Ana...
Date of Issue : 2022-06-17
Valid Till : 2025-07-02
Written Confirmation Number : WC-0082
Address of the Firm : API Division Kharakhadi, Plot No. 842-843, Kharakhadi, Padra Vadodara-391 450, G...
Date of Issue : 2022-07-04
Valid Till : 2025-07-03
Written Confirmation Number : WC-0040
Address of the Firm : Unit-I, Survey No.213, 214 & 255, Bonthapally Village, Jinnaram Mandal, Medak ...
Date of Issue : 2022-02-25
Valid Till : 2022-07-03
Written Confirmation Number : WC-0040A3
Address of the Firm : Unit-I, Survey No.213, 214 & 255, Bonthapally Village, Jinnaram Mandal, Medak D...
Date of Issue : 2022-06-17
Valid Till : 2025-07-14
Written Confirmation Number : WC-0021n
Address of the Firm : Sy. Nos: 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Man...
Date of Issue : 2019-07-26
Valid Till : 2022-08-08
Written Confirmation Number : WC-0383
Address of the Firm : Sy. No.455/A, 455/AA, 455/E & 455/EE Chandampet Village Shankarampet Mandal Meda...
Date of Issue : 2021-06-01
Valid Till : 2024-04-04
Written Confirmation Number : WC-0316n
Address of the Firm : Plot No.50-A,B,G & H, 64-A,B, C&D, 65-A,B,C&D, 66-A & B, 67-A & B, IDA, Kondapal...
Date of Issue : 2018-04-05
Valid Till : 2021-04-05
Written Confirmation Number : WC-316
Address of the Firm : Plot No.50-A,B,G & H, 64-A,B, C&D, 65-A,B,C&D, 66-A & B, 67-A & B, IDA, Kondapal...
Date of Issue : 2022-05-02
Valid Till : 2025-07-25
Written Confirmation Number : WC-0027
Address of the Firm : Unit-II, Survey No.14, IDA Gaddapotharam (Village), Kazipally, Jinnaram (Mandal)...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-012
Start Marketing Date : 2020-06-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-066
Start Marketing Date : 2023-11-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-062
Start Marketing Date : 2023-07-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 55111-909
Start Marketing Date : 2010-03-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 55111-905
Start Marketing Date : 2009-03-12
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52562-027
Start Marketing Date : 2021-03-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65977-0141
Start Marketing Date : 2009-01-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14501-0060
Start Marketing Date : 2010-03-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69766-053
Start Marketing Date : 2018-06-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65015-783
Start Marketing Date : 2015-01-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
About the Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialzation. With our...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
About the Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for critical and high-g...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...
About the Company : Chromo Laboratories India Pvt. Ltd, is a Hyderabad based Manufacturer of Intermediates and Active Pharmaceutical Ingredients. The manufacturing facility is located at Pashamylaram...
About the Company : Optimus is one of the fastest-growing pharmaceutical companies with 16 years of experience in providing the best quality of API, Intermediates & Finished formulations in Global mar...
About the Company : Founded by a group of highly committed Technocrats in year 2009, today Raks Pharma is a partner of choice for pharmaceutical companies across the globe to source Active Pharmaceuti...
About the Company : Spansules started in 2000 & now it is one of the leading pellets manufacturing pharmaceutical company with manufacturing facilities and R&D facilities spearheading landmark researc...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Dexilant-Generic (dexlansoprazole) is a proton pump inhibitor for healing erosive esophagitis and treating heartburn associated with non-erosive GERD.
Lead Product(s): Dexlansoprazole
Therapeutic Area: Gastroenterology Brand Name: Dexilant-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Devonian’s Subsidiary Launches Generic Dexlansoprazole (Dexilant®) in Canada
Details : Dexilant-Generic (dexlansoprazole) is a proton pump inhibitor for healing erosive esophagitis and treating heartburn associated with non-erosive GERD.
Brand Name : Dexilant-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - CAPSULE, DELAYED RELEASE;ORAL - 30MG
USFDA APPLICATION NUMBER - 22287
DOSAGE - CAPSULE, DELAYED RELEASE;ORAL - 60MG
USFDA APPLICATION NUMBER - 22287
Related Excipient Companies
Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Jai Radhe Sales
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
Dosage Form : Tablet
Grade : Oral
Application : Controlled & Modified Release
Excipient Details : It is a fine free flowing dry powder. Its major application is for Enteric/Delayed release coating and for drug delivery in small intestine.
Pharmacopoeia Ref : Monograph - EP, USP, JP
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid Methyl Methacrylate Copolymer
Dosage Form : Tablet
Grade : Oral
Application : Controlled & Modified Release
Excipient Details : It is a ready to use 30% dispersion in water and its major application is for Enteric/Delayed release coating for drug delivery in the duodenum.
Pharmacopoeia Ref : Monograph - EP, USP, JPE
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Dosage Form : Tablet
Grade : Oral
Application : Coating Systems & Additives
Excipient Details : It is a dry powder derived from a 30% aqueous dispersion (ECOPOL L 30 D 55). The major application is for Enteric/Delayed release coating for drug delivery in the duodenum.
Pharmacopoeia Ref : Monograph - EP, USP, JPE
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Dosage Form : Tablet
Grade : Oral
Application : Coating Systems & Additives
Excipient Details : It is a fine free flowing dry powder. Its major application is for Enteric/Delayed release coating and for drug delivery in colon.
Pharmacopoeia Ref : Monograph - EP, USP, JP
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid Methyl Methacrylate Copolymer
Dosage Form : Tablet
Grade : Oral
Application : Coating Systems & Additives
Dosage Form : Tablet
Grade : Oral
Application : Coating Systems & Additives
Dosage Form : Tablet
Grade : Oral
Application : Coating Systems & Additives
Excipient Details : It provides enteric protection at minimum weight gain, typically between 6.5 and 8.0%.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : METHACRYLIC ACID COPOLYMER TYPE A
Dosage Form : Tablet
Grade : Oral
Application : Coating Systems & Additives
Excipient Details : NSTACOAT EEN-SF is a ready-to-use acrylic-based enteric coating formulation in dry powder form for reconstitution.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : METHACRYLIC ACID COPOLYMER TYPE A
Dosage Form : Tablet
Grade : Oral
Brand Name : Instacoat EN Super II
Application : Coating Systems & Additives
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid Copolymer Type C
Dosage Form : Tablet
Grade : Oral
Application : Controlled & Modified Release
Excipient Details : Instamodel Blend is used to provide Extended Release from the dosage form.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
Dosage Form : Emulsion
Grade : Oral, Topical
Application : Thickeners and Stabilizers
Excipient Details : Modified Starch, Corn is a white powder and a unique emulsion stabilising starch derived from waxy maize.
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Fully Pregel Starch Corn is used as a binder in wet granulation in the manufacturing of tablets.
Pharmacopoeia Ref : USP/NF, Ph. Eur., Ch. P.
Technical Specs : NA
Ingredient(s) : Corn Starch, Pregelatinized
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
Dosage Form : Emulsion
Grade : Oral, Ophthalmic
Brand Name : Hydroxypropyl Methyl Cell...
Application : Emulsifying Agents
Excipient Details : Hydroxypropyl Methyl Cellulose is used as a film-former, disintegrant, thickener, and emulsifier in tablets, emulsions, and ophthalmic formulations.
Dosage Form : Tablet
Grade : Oral
Brand Name : Hydroxypropyl Methyl Cell...
Application : Fillers, Diluents & Binders
Excipient Details : Hydroxypropyl Methyl Cellulose (60E3) is used as a binding, coating, and granulating agent for the production of tablets.
Dosage Form : Tablet
Grade : Oral
Brand Name : Hydroxypropyl Methyl Cell...
Application : Controlled & Modified Release
Excipient Details : Hydroxypropyl Methyl Cellulose (75K100) is used in the production of controlled-release tablets.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Controlled & Modified Release
Fillers, Diluents & Binders
Solubilizers
Direct Compression
Thickeners and Stabilizers
Film Formers & Plasticizers
Co-Processed Excipients
Taste Masking
Parenteral
Emulsifying Agents
Disintegrants & Superdisintegrants
Empty Capsules
API Stability Enhancers
Rheology Modifiers
Lubricants & Glidants
Vegetarian Capsules
Coloring Agents
Chewable & Orodispersible Aids
Surfactant & Foaming Agents
Granulation
Topical
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
